Fatal injection of ranitidine: a case report

Antonio Oliva; Sara Partemi; Vincenzo Arena; Fabio De Giorgio; Catia Colecchi; Nadia Fucci; Vincenzo Lorenzo Pascali

doi:10.1186/1752-1947-2-232

Fatal injection of ranitidine: a case report

Antonio Oliva, Sara Partemi, Vincenzo Arena, Fabio De Giorgio, Catia Colecchi, Nadia Fucci, Vincenzo Lorenzo Pascali

Research output: Contribution to journal › Article

10 Citations (Scopus)

Abstract

ABSTRACT: INTRODUCTION: Ranitidine hydrochloride (Zantac(R)), a histamine-2-receptor antagonist, is a widely used medication with an excellent safety record. Anaphylactic reaction to ranitidine is an extremely rare event and a related death has never been described in the literature. CASE PRESENTATION: We present the clinical history, histological and toxicological data of a 51-year-old man with negative anamnesis for allergic events, who died suddenly after the intravenous administration of one phial of Zantac(R) 50 mg prescribed as a routine post-surgical prophylaxis for stress ulcer. CONCLUSION: Although the incidence of anaphylactic reactions related to ranitidine is low, caution needs to be exercised on administration of this drug. In addition, further study is needed to define strategies for the prevention of adverse drug reactions in hospitalized patients.

Original language	English
Pages (from-to)	230-232
Number of pages	3
Journal	Journal of Medical Case Reports
Volume	2
DOIs	https://doi.org/10.1186/1752-1947-2-232
Publication status	Published - 2008

Keywords

death
ranitidine

Access to Document

10.1186/1752-1947-2-232

Cite this

@article{7a9f09dc424a43e2919ac2a7325ccc26,

title = "Fatal injection of ranitidine: a case report",

abstract = "ABSTRACT: INTRODUCTION: Ranitidine hydrochloride (Zantac(R)), a histamine-2-receptor antagonist, is a widely used medication with an excellent safety record. Anaphylactic reaction to ranitidine is an extremely rare event and a related death has never been described in the literature. CASE PRESENTATION: We present the clinical history, histological and toxicological data of a 51-year-old man with negative anamnesis for allergic events, who died suddenly after the intravenous administration of one phial of Zantac(R) 50 mg prescribed as a routine post-surgical prophylaxis for stress ulcer. CONCLUSION: Although the incidence of anaphylactic reactions related to ranitidine is low, caution needs to be exercised on administration of this drug. In addition, further study is needed to define strategies for the prevention of adverse drug reactions in hospitalized patients.",

keywords = "death, ranitidine, death, ranitidine",

author = "Antonio Oliva and Sara Partemi and Vincenzo Arena and {De Giorgio}, Fabio and Catia Colecchi and Nadia Fucci and Pascali, {Vincenzo Lorenzo}",

year = "2008",

doi = "10.1186/1752-1947-2-232",

language = "English",

volume = "2",

pages = "230--232",

journal = "Journal of Medical Case Reports",

issn = "1752-1947",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Fatal injection of ranitidine: a case report

AU - Oliva, Antonio

AU - Partemi, Sara

AU - Arena, Vincenzo

AU - De Giorgio, Fabio

AU - Colecchi, Catia

AU - Fucci, Nadia

AU - Pascali, Vincenzo Lorenzo

PY - 2008

Y1 - 2008

N2 - ABSTRACT: INTRODUCTION: Ranitidine hydrochloride (Zantac(R)), a histamine-2-receptor antagonist, is a widely used medication with an excellent safety record. Anaphylactic reaction to ranitidine is an extremely rare event and a related death has never been described in the literature. CASE PRESENTATION: We present the clinical history, histological and toxicological data of a 51-year-old man with negative anamnesis for allergic events, who died suddenly after the intravenous administration of one phial of Zantac(R) 50 mg prescribed as a routine post-surgical prophylaxis for stress ulcer. CONCLUSION: Although the incidence of anaphylactic reactions related to ranitidine is low, caution needs to be exercised on administration of this drug. In addition, further study is needed to define strategies for the prevention of adverse drug reactions in hospitalized patients.

AB - ABSTRACT: INTRODUCTION: Ranitidine hydrochloride (Zantac(R)), a histamine-2-receptor antagonist, is a widely used medication with an excellent safety record. Anaphylactic reaction to ranitidine is an extremely rare event and a related death has never been described in the literature. CASE PRESENTATION: We present the clinical history, histological and toxicological data of a 51-year-old man with negative anamnesis for allergic events, who died suddenly after the intravenous administration of one phial of Zantac(R) 50 mg prescribed as a routine post-surgical prophylaxis for stress ulcer. CONCLUSION: Although the incidence of anaphylactic reactions related to ranitidine is low, caution needs to be exercised on administration of this drug. In addition, further study is needed to define strategies for the prevention of adverse drug reactions in hospitalized patients.

KW - death

KW - ranitidine

KW - death

KW - ranitidine

UR - http://hdl.handle.net/10807/6798

U2 - 10.1186/1752-1947-2-232

DO - 10.1186/1752-1947-2-232

M3 - Article

SN - 1752-1947

VL - 2

SP - 230

EP - 232

JO - Journal of Medical Case Reports

JF - Journal of Medical Case Reports

ER -

Fatal injection of ranitidine: a case report

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this